About the Authors

Alexander Y. Deneka

Erica.Golemis@fccc.edu (EG); Alexander.Deneka@fccc.edu (AD)

Affiliations Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America, Department of Biochemistry, Kazan Federal University, Kazan, Russia

Leora Haber

Affiliation Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America

Meghan C. Kopp

Affiliations Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America, Program in Molecular and Cell Biology and Genetics, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America

Anna V. Gaponova

Affiliations Laboratory of Genome Engineering, Moscow Institute of Physics and Technology, Dolgoprudny, Russia, Immanuel Kant Baltic Federal University, Konigsberg, Russia

Anna S. Nikonova

Affiliation Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America

Erica A. Golemis

Erica.Golemis@fccc.edu (EG); Alexander.Deneka@fccc.edu (AD)

Affiliation Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America

Competing Interests

David Proia and Synta Pharmaceuticals provided STA- 8666 for this study but no funding. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceptualization: EG AD AN. Funding acquisition: EG. Investigation: AD LH AG AN MK. Methodology: EG AD AN AG. Project administration: EG AD. Resources: AN AD. Supervision: EG. Validation: EG AD. Visualization: AD. Writing – original draft: AD. Writing – review & editing: AD EG.